IF
HZNP

Ironwood Financial’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ironwood Financial’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3
Closed – – 483
2014
Q4 		$0 Buy
+3
New +$38 ﹤0.01% 441

Other funds holding HZNP

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Ironwood Financial's HZNP Position: Q1 2015 in Review

Ironwood Financial sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2015, closing a stake of 3 shares.

Ironwood Financial first reported a position in HZNP in Q4 2014 and held it in 1 quarter. The position peaked at $0 in Q4 2014. 177 funds tracked by Wall St. Rank hold HZNP as of Q1 2015.

  • Ironwood Financial reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2015 after selling out during the quarter.
  • Ironwood Financial sold 3 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2015.
  • Ironwood Financial first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 1 quarter.
  • Ironwood Financial's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $0 in Q4 2014.
  • 177 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2015.

Based on Ironwood Financial's 13F filing for Q1 2015, filed 6 May 2015.